688382 益方生物-U
已收盘 05-15 15:00:00
资讯
新帖
简况
每周股票复盘：益方生物（688382）一季度收入增419.51%
证券之星 · 05-02
每周股票复盘：益方生物（688382）一季度收入增419.51%
益方生物(688382.SH)发布一季度业绩，归母净亏损4437万元
智通财经 · 04-28
益方生物(688382.SH)发布一季度业绩，归母净亏损4437万元
图解益方生物一季报：第一季度单季净利润同比增长22.84%
证券之星 · 04-28
图解益方生物一季报：第一季度单季净利润同比增长22.84%
长城国瑞证券：给予益方生物买入评级
证券之星 · 04-22
长城国瑞证券：给予益方生物买入评级
4月22日益方生物涨9.09%，平安匠心优选混合A基金重仓该股
证券之星 · 04-22
4月22日益方生物涨9.09%，平安匠心优选混合A基金重仓该股
益方生物（688382）披露提请股东会授权董事会以简易程序向特定对象发行股票的公告，4月15日股价上涨0.47%
证券之星 · 04-15
益方生物（688382）披露提请股东会授权董事会以简易程序向特定对象发行股票的公告，4月15日股价上涨0.47%
每周股票复盘：益方生物（688382）因股价涨幅达15%登龙虎榜
证券之星 · 04-05
每周股票复盘：益方生物（688382）因股价涨幅达15%登龙虎榜
4月1日益方生物（688382）龙虎榜数据：机构净买入6154.66万元，北向资金净买入1469.8万元
证券之星 · 04-01
4月1日益方生物（688382）龙虎榜数据：机构净买入6154.66万元，北向资金净买入1469.8万元
每周股票复盘：益方生物（688382）D-2570完成银屑病III期入组
证券之星 · 03-29
每周股票复盘：益方生物（688382）D-2570完成银屑病III期入组
益方生物(688382.SH)终止实施2025年限制性股票激励计划
智通财经 · 03-27
益方生物(688382.SH)终止实施2025年限制性股票激励计划
益方生物(688382.SH)：D-2570治疗银屑病注册性III期临床试验完成全部受试者入组
智通财经 · 03-26
益方生物(688382.SH)：D-2570治疗银屑病注册性III期临床试验完成全部受试者入组
3月23日益方生物跌5.20%，长城医药产业精选混合发起式A基金重仓该股
证券之星 · 03-23
3月23日益方生物跌5.20%，长城医药产业精选混合发起式A基金重仓该股
股市必读：益方生物（688382）今年截至3月20日累计跌幅已超35%
证券之星 · 03-23
股市必读：益方生物（688382）今年截至3月20日累计跌幅已超35%
每周股票复盘：益方生物（688382）D-2570获FDA批准开展银屑病II期临床
证券之星 · 03-22
每周股票复盘：益方生物（688382）D-2570获FDA批准开展银屑病II期临床
管线研发“烧钱”不止，益方生物赴港上市“补血”
市场资讯 · 03-19
管线研发“烧钱”不止，益方生物赴港上市“补血”
益方生物(688382.SH)：D-2570在美国获准开展银屑病II期临床试验
智通财经 · 03-18
益方生物(688382.SH)：D-2570在美国获准开展银屑病II期临床试验
【机构调研记录】嘉实基金调研益方生物、思特威等3只个股（附名单）
证券之星 · 03-16
【机构调研记录】嘉实基金调研益方生物、思特威等3只个股（附名单）
【机构调研记录】南方基金调研三友化工、益方生物等4只个股（附名单）
证券之星 · 03-16
【机构调研记录】南方基金调研三友化工、益方生物等4只个股（附名单）
3月13日益方生物跌6.20%，长城医药产业精选混合发起式A基金重仓该股
证券之星 · 03-13
3月13日益方生物跌6.20%，长城医药产业精选混合发起式A基金重仓该股
3月11日益方生物跌5.71%，长城医药产业精选混合发起式A基金重仓该股
证券之星 · 03-11
3月11日益方生物跌5.71%，长城医药产业精选混合发起式A基金重仓该股
公司概况
公司名称：
益方生物科技(上海)股份有限公司
所属行业：
医药制造业
上市日期：
2022-07-25
主营业务：
益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是技术授权、技术合作。截至报告期末，公司新申请发明专利85项，累计获得境内外发明专利授权157项。
发行价格：
18.12
{"stockData":{"symbol":"688382","market":"SH","secType":"STK","nameCN":"益方生物-U","latestPrice":21.53,"timestamp":1778828400000,"preClose":22.06,"halted":0,"volume":12691662,"delay":0,"changeRate":-0.024,"floatShares":578000000,"shares":578000000,"eps":-0.5252,"marketStatus":"已收盘","change":-0.53,"latestTime":"05-15 15:00:00","open":21.89,"high":22.35,"low":21.31,"amount":276000000,"amplitude":0.0471,"askPrice":21.54,"askSize":8,"bidPrice":21.53,"bidSize":45,"shortable":0,"etf":0,"ttmEps":-0.5252,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":5,"adr":0,"adjPreClose":22.06,"symbolType":"stock_kcb","openAndCloseTimeList":[[1778808600000,1778815800000],[1778821200000,1778828400000]],"highLimit":24.27,"lowLimit":19.85,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":578348491,"isCdr":false,"pbRate":8.32,"roa":"--","roe":"--","epsLYR":-0.5479,"committee":-0.606526,"marketValue":12452000000,"turnoverRate":0.0219,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-18。","afterMarket":{"amount":0,"volume":0,"close":21.53,"buyVolume":0,"sellVolume":500,"time":1778830437559,"indexStatus":"已收盘 05-15 15:30:00","preClose":22.06},"floatMarketCap":12452000000},"requestUrl":"/m/hq/s/688382/wiki","defaultTab":"wiki","newsList":[{"id":"2632562833","title":"每周股票复盘：益方生物（688382）一季度收入增419.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632562833","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632562833?lang=zh_cn&edition=full","pubTime":"2026-05-02 05:13","pubTimestamp":1777669992,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，益方生物报收于23.3元，较上周的22.28元上涨4.58%。本周，益方生物4月30日盘中最高价报24.05元。业绩披露要点：2026年一季度主营收入4254.24万元，同比上升419.51%。股本股东变化股东户数变动截至2026年3月31日，益方生物股东户数为1.77万户，较2025年12月31日增加2825.0户，增幅18.96%。户均持股数量由上期的3.88万股降至3.26万股，户均持股市值为62.06万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630558638","title":"益方生物(688382.SH)发布一季度业绩，归母净亏损4437万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630558638","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630558638?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:45","pubTimestamp":1777387551,"startTime":"0","endTime":"0","summary":"智通财经APP讯，益方生物(688382.SH)披露2026年第一季度报告，报告期公司实现营收4254万元，同比增长419.51%;归母净利润亏损4437万元;扣非净利润亏损4545万元。基本每股收益-0.08元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"益方生物(688382.SH)发布一季度业绩，归母净亏损4437万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630089273","title":"图解益方生物一季报：第一季度单季净利润同比增长22.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630089273","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630089273?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:43","pubTimestamp":1777373004,"startTime":"0","endTime":"0","summary":"证券之星消息，益方生物2026年一季报显示，一季度公司主营收入4254.24万元，同比上升419.51%；归母净利润-4436.72万元，同比上升22.84%；扣非净利润-4545.15万元，同比上升21.93%；负债率6.58%，财务费用-443.0万元，毛利率96.17%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800054602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629048348","title":"长城国瑞证券：给予益方生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2629048348","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629048348?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:07","pubTimestamp":1776856055,"startTime":"0","endTime":"0","summary":"长城国瑞证券有限公司胡晨曦,魏钰琪近期对益方生物进行研究并发布了研究报告《业绩受授权合作收入确认扰动 看好TYK2自免产品BIC潜力》，给予益方生物买入评级。 事件点评： 公司 2025 年业绩承压源于授权收入确认节奏波动。格索雷塞已于 2024 年 11 月获 NMPA 批准上市， 用于治疗至少接受过一种系统性治疗的 KRASG12C 突变型的晚期非小细胞肺癌 成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200046407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629015115","title":"4月22日益方生物涨9.09%，平安匠心优选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629015115","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629015115?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:29","pubTimestamp":1776846569,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日益方生物涨9.09%，收盘报23.28元，换手率4.54%，成交量26.24万手，成交额5.93亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共27家，其中持有数量最多的公募基金为平安基金的平安匠心优选混合A。平安匠心优选混合A目前规模为21.21亿元，最新净值1.6219，较上一交易日下跌0.09%，近一年上涨46.04%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200037735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627840764","title":"益方生物（688382）披露提请股东会授权董事会以简易程序向特定对象发行股票的公告，4月15日股价上涨0.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627840764","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627840764?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:07","pubTimestamp":1776244050,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘，益方生物报收于21.27元，较前一交易日上涨0.47%，最新总市值为123.01亿元。该股当日开盘21.77元，最高22.2元，最低20.44元，成交额达4.98亿元，换手率为4.08%。本次授权尚需提交公司2025年年度股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500030503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625616272","title":"每周股票复盘：益方生物（688382）因股价涨幅达15%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2625616272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625616272?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:31","pubTimestamp":1775327469,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，益方生物报收于22.8元，较上周的19.99元上涨14.06%。本周，益方生物4月2日盘中最高价报23.96元。3月31日盘中最低价报18.94元。益方生物当前最新总市值131.86亿元，在化学制药板块市值排名43/150，在两市A股市值排名1471/5193。本周关注点交易信息汇总：益方生物因日收盘价格涨幅达到15%登上龙虎榜。此次是近5个交易日内第1次上榜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624759945","title":"4月1日益方生物（688382）龙虎榜数据：机构净买入6154.66万元，北向资金净买入1469.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624759945","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624759945?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:21","pubTimestamp":1775035270,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月1日公布的交易公开信息显示，益方生物因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月1日收盘，益方生物报收于22.08元，上涨16.09%，换手率6.59%，成交量38.12万手，成交额8.11亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入6154.66万元，北向资金合计净买入1469.8万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100031656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623096387","title":"每周股票复盘：益方生物（688382）D-2570完成银屑病III期入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2623096387","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623096387?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:38","pubTimestamp":1774719490,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，益方生物报收于19.99元，较上周的17.68元上涨13.07%。本周关注点来自公司公告汇总：D-2570治疗银屑病注册性III期临床试验完成全部受试者入组。来自公司公告汇总：益方生物终止2025年限制性股票激励计划，因市场环境及股价波动影响。公司公告汇总益方生物自愿披露，其自主研发的TYK2抑制剂D-2570用于治疗中重度斑块状银屑病的注册性III期临床试验已完成全部受试者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622845605","title":"益方生物(688382.SH)终止实施2025年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2622845605","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622845605?lang=zh_cn&edition=full","pubTime":"2026-03-27 15:38","pubTimestamp":1774597130,"startTime":"0","endTime":"0","summary":"智通财经APP讯，益方生物(688382.SH)发布公告，鉴于当前宏观环境、资本市场以及二级市场价格波动等多方面影响，若继续实施2025年限制性股票激励计划，将难以达到预期的激励目的和激励效果。经公司董事会审慎研究，公司拟终止实施《益方生物科技(上海)股份有限公司2025年限制性股票激励计划(草案)》，与之配套的《益方生物科技(上海)股份有限公司2025年限制性股票激励计划实施考核管理办法》等相关文件一并终止。后续公司将根据外部市场环境适时推出更符合公司发展战略和经营目标的、能有效将股东、公司和员工的中长期利益相结合的激励计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622830947","title":"益方生物(688382.SH)：D-2570治疗银屑病注册性III期临床试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2622830947","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622830947?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:48","pubTimestamp":1774514885,"startTime":"0","endTime":"0","summary":"智通财经APP讯，益方生物(688382.SH)公告，公司自主研发的TYK2抑制剂D-2570用于治疗中重度斑块状银屑病(PsO)的注册性III期临床试验已于近日完成全部受试者入组。公告显示，D-2570是公司自主研发的一款靶向酪氨酸激酶2(TYK2)的新型口服选择性抑制剂，用于治疗银屑病等自身免疫性疾病。D-2570通过选择性结合TYK2假激酶域JH2部位，抑制TYK2激酶的活性，进而阻断TYK2依赖性的细胞因子信号传导介导的STAT蛋白的磷酸化，抑制炎症因子释放，参与免疫调节。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","688382","III","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621768627","title":"3月23日益方生物跌5.20%，长城医药产业精选混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621768627","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621768627?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:39","pubTimestamp":1774255171,"startTime":"0","endTime":"0","summary":"证券之星消息，3月23日益方生物跌5.20%创60日新低，收盘报16.76元，换手率2.6%，成交量15.04万手，成交额2.58亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共70家，其中持有数量最多的公募基金为长城基金的长城医药产业精选混合发起式A。长城医药产业精选混合发起式A目前规模为3.87亿元，最新净值1.5877，较上一交易日下跌1.19%，近一年上涨33.48%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621745766","title":"股市必读：益方生物（688382）今年截至3月20日累计跌幅已超35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621745766","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621745766?lang=zh_cn&edition=full","pubTime":"2026-03-23 02:43","pubTimestamp":1774204989,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，益方生物报收于17.68元，下跌3.86%，换手率2.65%，成交量15.32万手，成交额2.78亿元。当日关注点来自交易信息汇总：益方生物股价连续4日下跌，年内累计跌幅达35.08%。该股已连续4日下跌，当年累计跌幅35.08%。资金流向3月20日主力资金净流出954.05万元，占总成交额3.44%；游资资金净流出2379.21万元，占总成交额8.57%；散户资金净流入3333.26万元，占总成交额12.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300000908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621796086","title":"每周股票复盘：益方生物（688382）D-2570获FDA批准开展银屑病II期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2621796086","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621796086?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:27","pubTimestamp":1774117630,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，益方生物报收于17.68元，较上周的18.91元下跌6.5%。本周，益方生物3月17日盘中最高价报20.38元。本周关注点公司公告汇总：D-2570获美国FDA批准开展银屑病II期临床试验。目前，D-2570在溃疡性结肠炎、银屑病关节炎、系统性红斑狼疮等适应症的临床试验持续推进中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620248572","title":"管线研发“烧钱”不止，益方生物赴港上市“补血”","url":"https://stock-news.laohu8.com/highlight/detail?id=2620248572","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620248572?lang=zh_cn&edition=full","pubTime":"2026-03-19 16:21","pubTimestamp":1773908460,"startTime":"0","endTime":"0","summary":" 作为专注肿瘤、代谢及自身免疫疾病的研发型创新药企，益方生物已成功推出贝福替尼、格索雷塞两款上市并纳入医保的核心产品。 在持续研发投入与现金流不断消耗的双重压力下，为保障D-0502、D-2570等核心管线顺利推进临床，益方生物启动港股IPO寻求资本补充。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-03-19/doc-inhrpfxy1531013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620980239","title":"益方生物(688382.SH)：D-2570在美国获准开展银屑病II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2620980239","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620980239?lang=zh_cn&edition=full","pubTime":"2026-03-18 17:23","pubTimestamp":1773825820,"startTime":"0","endTime":"0","summary":"智通财经APP讯，益方生物 发布公告，公司向美国食品药品监督管理局提交的关于D-2570单药治疗银屑病的II期临床试验申请已于近日到达30天默认期，未收到FDA的反对意见。根据相关规定，D-2570在美国单药治疗PsO的II期临床试验已正式获得批准。此前，公司已完成了在中国开展的D-2570针对银屑病的II期临床试验，研究结果显示，与安慰剂组相比，治疗第12周时，D-2570在皮损清除及疾病严重程度改善方面表现出显著疗效，整体安全性与耐受性良好。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"益方生物(688382.SH)：D-2570在美国获准开展银屑病II期临床试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619618481","title":"【机构调研记录】嘉实基金调研益方生物、思特威等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2619618481","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619618481?lang=zh_cn&edition=full","pubTime":"2026-03-16 08:01","pubTimestamp":1773619294,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及3月13日披露的机构调研信息，嘉实基金近期对3家上市公司进行了调研，相关名单如下：1）益方生物 调研纪要：D-2570针对中、重度活动性溃疡性结肠炎的II期临床试验已于2025年5月完成首例患者给药，银屑病III期临床试验正按计划推进。2）思特威 调研纪要：2025年公司实现营业收入90.31亿元，较上年同比增加51.32%；归母净利润达10.01亿元，同比增长154.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600001648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0214","BK0231","688382","688213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619481634","title":"【机构调研记录】南方基金调研三友化工、益方生物等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2619481634","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619481634?lang=zh_cn&edition=full","pubTime":"2026-03-16 08:01","pubTimestamp":1773619293,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及3月13日披露的机构调研信息，南方基金近期对4家上市公司进行了调研，相关名单如下：1）三友化工 调研纪要：公司主导产品开工率约九成，库存低位运行。控股股东表示无减持计划，解禁为正常流通安排，相关承诺仍在履行中。4）普蕊斯 调研纪要：2025年，中国药物临床试验数量达5,173项，同比增长6.44%；1类创新药获批76个，同比增长58%；创新药对外授权交易总金额超1,300亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600001644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0196","BK0188","BK0229","BK0239","688382","600409","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619162395","title":"3月13日益方生物跌6.20%，长城医药产业精选混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619162395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619162395?lang=zh_cn&edition=full","pubTime":"2026-03-13 16:22","pubTimestamp":1773390156,"startTime":"0","endTime":"0","summary":"证券之星消息，3月13日益方生物跌6.20%创60日新低，收盘报18.91元，换手率3.61%，成交量20.88万手，成交额4.0亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共70家，其中持有数量最多的公募基金为长城基金的长城医药产业精选混合发起式A。长城医药产业精选混合发起式A目前规模为3.87亿元，最新净值1.5673，较上一交易日下跌2.94%，近一年上涨39.07%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300027075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618912874","title":"3月11日益方生物跌5.71%，长城医药产业精选混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618912874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618912874?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:20","pubTimestamp":1773217234,"startTime":"0","endTime":"0","summary":"证券之星消息，3月11日益方生物跌5.71%，收盘报21.15元，换手率2.42%，成交量14.01万手，成交额3.0亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共70家，其中持有数量最多的公募基金为长城基金的长城医药产业精选混合发起式A。长城医药产业精选混合发起式A目前规模为3.87亿元，最新净值1.6497，较上一交易日上涨5.77%，近一年上涨42.56%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100026229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778941112556,"stockEarnings":[{"period":"1week","weight":-0.0271},{"period":"1month","weight":0.0122},{"period":"3month","weight":-0.0218},{"period":"6month","weight":-0.2311},{"period":"1year","weight":0.0857},{"period":"ytd","weight":-0.2096}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.0363},{"period":"1year","weight":0.2232},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"益方生物科技(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17726人(较上一季度增加18.96%)","perCapita":"32627股","listingDate":"2022-07-25","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路67弄4号210室","registeredCapital":"57834万元","survey":" 益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是技术授权、技术合作。截至报告期末，公司新申请发明专利85项，累计获得境内外发明专利授权157项。","listedPrice":18.12},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"益方生物-U(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供益方生物-U(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"益方生物-U,688382,益方生物-U股票,益方生物-U股票老虎,益方生物-U股票老虎国际,益方生物-U行情,益方生物-U股票行情,益方生物-U股价,益方生物-U股市,益方生物-U股票价格,益方生物-U股票交易,益方生物-U股票购买,益方生物-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"益方生物-U(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供益方生物-U(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}